However, overall survival data were updated in the final analysis with a 27% reduction in the risk of death with XTANDI + LHRH therapy* vs placebo + LHRH therapy* (HR = 0.73 [95% CI, 0.61-0.88]; P = 0.0011).

33% reduction in the risk of death with XTANDI + LHRH therapy* vs NSAA + LHRH therapy* (HR = 0.67 [95% CI, 0.52-0.86]; P = 0.002).
